

Valerio Brisigotti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3848372/publications.pdf>

Version: 2024-02-01

26
papers

422
citations

687363

13
h-index

752698

20
g-index

27
all docs

27
docs citations

27
times ranked

323
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy and safety of topical resorcinol 15% versus topical clindamycin 1% in the management of mild to moderate hidradenitis suppurativa: A retrospective study. <i>Dermatologic Therapy</i> , 2022, 35, e15439.	1.7	11
2	Management of patients with pemphigus vulgaris during the COVID-19 pandemic: Experience of a second level dermatology center. <i>Australasian Journal of Dermatology</i> , 2021, 62, e158-e159.	0.7	4
3	Lymecycline vs. clindamycin plus rifampicin in hidradenitis suppurativa treatment: clinical and ultrasonography evaluation. <i>Clinical and Experimental Dermatology</i> , 2021, 46, 96-102.	1.3	15
4	Paraoxonase-2: A potential biomarker for skin cancer aggressiveness. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13452.	3.4	34
5	Primary Dermal Melanoma: A Rare Clinicopathological Variant Mimicking Metastatic Melanoma. <i>Dermatopathology (Basel, Switzerland)</i> , 2021, 8, 29-32.	1.5	3
6	Nicotinamide N-methyltransferase gene silencing enhances chemosensitivity of melanoma cell lines. <i>Pigment Cell and Melanoma Research</i> , 2021, 34, 1039-1048.	3.3	30
7	Differential immunohistochemical expression of paraoxonase-2 in actinic keratosis and squamous cell carcinoma. <i>Human Cell</i> , 2021, 34, 1929-1931.	2.7	18
8	Beyond Nicotinamide Metabolism: Potential Role of Nicotinamide N-Methyltransferase as a Biomarker in Skin Cancers. <i>Cancers</i> , 2021, 13, 4943.	3.7	37
9	Differential expression of nicotinamide N-methyltransferase in cutaneous keratoacanthoma and squamous cell carcinoma: an immunohistochemical study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e121-e123.	2.4	2
10	Time to restart: protocol of resumption of activities of a dermatological clinic of a level II hospital in the COVID-19 era. <i>International Journal of Dermatology</i> , 2020, 59, 1411-1413.	1.0	3
11	Management of patients with hidradenitis suppurativa during the COVID-19 pandemic: Risk and benefit of immunomodulatory therapy. <i>Dermatologic Therapy</i> , 2020, 33, e14256.	1.7	7
12	Metabolic, pharmacokinetic, and toxicological issues of biologic therapies currently used in the treatment of hidradenitis suppurativa. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2020, 16, 1019-1037.	3.3	7
13	Paraoxonase-2 Silencing Enhances Sensitivity of A375 Melanoma Cells to Treatment with Cisplatin. <i>Antioxidants</i> , 2020, 9, 1238.	5.1	37
14	Active implications for dermatologists in "SARS-CoV-2 ERA™": Personal experience and review of literature. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 1626-1632.	2.4	20
15	How can I take care of you? The dermatologist meets patients' needs during the COVID-19 pandemic. <i>Dermatologic Therapy</i> , 2020, 33, e13740.	1.7	14
16	Global coronavirus pandemic (SARS-CoV-2): Past , present , and future of pediatric dermatology. <i>Dermatologic Therapy</i> , 2020, 33, e13767.	1.7	3
17	Acne agminata in Crohn's disease: A diagnostic and therapeutic challenge case for dermatologists. <i>Dermatologic Therapy</i> , 2020, 33, e13935.	1.7	2
18	Efficacy and safety of topical resorcinol 15% as long-term treatment of mild to moderate hidradenitis suppurativa: a valid alternative to clindamycin in the panorama of antibiotic resistance. <i>British Journal of Dermatology</i> , 2020, 183, 1117-1119.	1.5	18

#	ARTICLE	IF	CITATIONS
19	Efficacy of oral zinc and nicotinamide as maintenance therapy for mild/moderate hidradenitis suppurativa: A controlled retrospective clinical study. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 665-667.	1.2	22
20	Novel Therapeutic Approaches and Targets for the Treatment of Neutrophilic Dermatoses, Management of Patients with Neutrophilic Dermatoses and Future Directions in the Era of Biologic Treatment. <i>Current Pharmaceutical Biotechnology</i> , 2020, 22, 46-58.	1.6	4
21	Nicotinamide N-methyltransferase in nonmelanoma skin cancers. <i>European Journal of Clinical Investigation</i> , 2019, 49, e13175.	3.4	22
22	Hidradenitis suppurativa in a prepubertal case series: a call for specific guidelines. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 28-31.	2.4	25
23	Metabolic, pharmacokinetic, and toxicological issues surrounding dapsone. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2019, 15, 367-379.	3.3	26
24	Nicotinamide N-methyltransferase: potential involvement in cutaneous malignant melanoma. <i>Melanoma Research</i> , 2018, 28, 82-88.	1.2	35
25	Biologic Therapy in Psoriasis (Part I): Efficacy and Safety of Tumor Necrosis Factor-Î± Inhibitors. <i>Current Pharmaceutical Biotechnology</i> , 2018, 18, 945-963.	1.6	8
26	Finally, recurrent pyoderma gangrenosum treated with Adalimumab: case report and review of the literature. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 1245-1247.	2.4	15